Education
About Us
Working with TipRanks
Follow Us
Merck KGaA (GB:0O14)
LSE:0O14
0O14 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€100.90 - €170.80
Previous CloseN/A
Volume74.17K
Average Volume (3M)48.88K
Market Cap
€46.39B
Enterprise Value€55.88B
Total Cash (Recent Filing)€1.57B
Total Debt (Recent Filing)€9.40B
Price to Earnings (P/E)16.2
Beta0.90
Next Earnings
Nov 13, 2025EPS Estimate
2.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.02
Shares Outstanding129,242,250
10 Day Avg. Volume44,528
30 Day Avg. Volume48,885
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€144.44Price Target Upside35.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Electronics DivisionElectronics recovery is playing out due to AI, improving the profile of the division.
Growth ExpectationsA return to growth in Life Sciences and Process Solutions for the first time in five quarters is expected to give additional confidence to investors on future growth expectations.
ValuationAnalyst re-iterates BUY as MRK is attractively valued compared to its end markets and peers.
Bears Say
EBITDA QualityThere is a negative perception surrounding Healthcare-driven EBITDA beats due to cost releases, which investors might see as lower quality compared to topline-driven growth.
Life Sciences ChallengesThere is a clear lack of visibility on FY25 Life Sciences trends, with Bioprocessing numbers below mid-term expectations.
Sales ExpectationsThe guidance indicates that the upper end of the sales range is out of reach, aligning with previous messaging but possibly disappointing investors hoping for higher sales figures.
Merck KGaA News
0O14 FAQ
What was Merck KGaA’s price range in the past 12 months?
Merck KGaA lowest share price was €100.90 and its highest was €170.80 in the past 12 months.
What is Merck KGaA’s market cap?
Merck KGaA’s market cap is €46.39B.
When is Merck KGaA’s upcoming earnings report date?
Merck KGaA’s upcoming earnings report date is Nov 13, 2025 which is in 56 days.
How were Merck KGaA’s earnings last quarter?
Merck KGaA released its earnings results on Aug 07, 2025. The company reported €2.02 earnings per share for the quarter, missing the consensus estimate of €2.138 by -€0.118.
Is Merck KGaA overvalued?
According to Wall Street analysts Merck KGaA’s price is currently Undervalued.
Does Merck KGaA pay dividends?
Merck KGaA does not currently pay dividends.
What is Merck KGaA’s EPS estimate?
Merck KGaA’s EPS estimate is 2.09.
How many shares outstanding does Merck KGaA have?
Merck KGaA has 129,242,250 shares outstanding.
What happened to Merck KGaA’s price movement after its last earnings report?
Merck KGaA reported an EPS of €2.02 in its last earnings report, missing expectations of €2.138. Following the earnings report the stock price went down -0.834%.
Which hedge fund is a major shareholder of Merck KGaA?
Currently, no hedge funds are holding shares in GB:0O14
Merck KGaA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€144.44 (35.69% Upside)
€144.44 (35.69% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.65%
12-Months-Change
Fundamentals
Return on Equity
10.08%
Trailing 12-Months
Asset Growth
-5.06%
Trailing 12-Months
Company Description
Merck KGaA
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment also provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. The Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.
0O14 Stock 12 Month Forecast
Average Price Target
€144.44
▲(35.69% Upside)
Technical Analysis
Options Prices
Currently, No data available
---